Cargando…

Right ventricular–pulmonary artery coupling in cardiac resynchronization therapy: evolution and prognosis

AIMS: Chronic pressure overload and right ventricular (RV) dysfunction can lead to RV–pulmonary artery (PA) uncoupling in patients with heart failure. The evolution and prognostic values of RV–PA coupling assessed by echocardiography in patients undergoing cardiac resynchronization therapy (CRT) hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Stassen, Jan, Galloo, Xavier, Hirasawa, Kensuke, Chimed, Surenjav, Marsan, Nina Ajmone, Delgado, Victoria, van der Bijl, Pieter, Bax, Jeroen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065855/
https://www.ncbi.nlm.nih.gov/pubmed/35266319
http://dx.doi.org/10.1002/ehf2.13857
Descripción
Sumario:AIMS: Chronic pressure overload and right ventricular (RV) dysfunction can lead to RV–pulmonary artery (PA) uncoupling in patients with heart failure. The evolution and prognostic values of RV–PA coupling assessed by echocardiography in patients undergoing cardiac resynchronization therapy (CRT) have not been thoroughly investigated. The aim of this study was to evaluate the evolution and prognostic value of tricuspid annular plane systolic excursion (TAPSE)/pulmonary artery systolic pressure (PASP) ratio in CRT recipients. METHODS AND RESULTS: The RV–PA coupling was measured non‐invasively with echocardiography using the TAPSE/PASP ratio at baseline and 6 month follow‐up in CRT recipients. The cut‐off value for TAPSE/PASP uncoupling was derived from spline curve analysis (i.e. <0.45 mm/mmHg). The primary endpoint was all‐cause mortality. A total of 807 patients (age 66 ± 11 years, 76% men) were analysed. During a median follow‐up of 97 (54–143) months, 483 (60%) patients died. Survival rates at 3 and 5 year follow‐up were significantly lower for patients with a TAPSE/PASP ratio <0.45 mm/mmHg (76% and 58%, respectively), compared with those with a TAPSE/PASP ratio ≥0.45 mm/mmHg (91% and 82%, respectively) (P < 0.001). On multivariable analysis, TAPSE/PASP ratio <0.45 mm/mmHg (hazard ratio 1.437; 95% confidence interval: 1.145–1.805; P = 0.002) was independently associated with all‐cause mortality, whereas TAPSE <17 mm (hazard ratio 1.237; 95% confidence interval: 0.990–1.546; P = 0.061) was not. In addition, no improvement of the TAPSE/PASP ratio after CRT implantation was independently associated with worse survival. CONCLUSIONS: The TAPSE/PASP ratio at baseline is independently associated with long‐term outcomes in CRT recipients. The baseline TAPSE/PASP ratio has incremental value over TAPSE, which does not take account of RV afterload. A lack of improvement in the TAPSE/PASP ratio after CRT implantation is associated with worse survival.